Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.53 |
| ▸ | MMP9 | P14780 | 2/20 | 0.53 |
| ▸ | PLAU | P00749 | 5/20 | 0.44 |
| ▸ | HPN | P05981 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421131 | 1.00 | MMP2 (0.53) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL284484 | 0.87 | MMP2 (0.56) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL1115907 | 0.87 | MMP2 (0.56) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL6571626 | 0.84 | MMP9 (0.65) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL796114 | 0.84 | MMP9 (0.65) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL5470148 | 0.83 | MMP2 (0.57) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL5470145 | 0.83 | MMP2 (0.57) | MMP2MMP9PLAUHPNTDP1 | |
| Hydrochloric Acid SCHEMBL14059215 | 0.83 | MMP9 (0.64) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL28509074 | 0.83 | MMP2 (0.60) | MMP2MMP9PLAUHPNTDP1 | |
| SCHEMBL8965842 | 0.82 | MMP9 (0.65) | MMP2MMP9PLAUHPNTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146930-A1 | 177-LU LABELED ACTIVE SITE INHIBITED FACTOR VII | MINERVA IMAGING APS (DK) | 2023-05-11 | — | — | US | disclosed |
| EP-3402537-B1 | QUANTITATIVE PET IMAGING OF TISSUE FACTOR EXPRESSION USING 18F-LABELLED ACTIVE SITE INHIBITED FACTOR VII | RIGSHOSPITALET (DK) | 2021-01-06 | — | — | EP | disclosed |
| EP-3541432-A1 | 177-LU LABELED ACTIVE SITE INHIBITED FACTOR VII | Minerva Imaging ApS (DK) | 2019-09-25 | — | — | EP | disclosed |
| US-20190015532-A1 | QUANTITATIVE PET IMAGING OF TISSUE FACTOR EXPRESSION USING 18F-LABLED ACTIVE SITE INHIBITED FACTOR VII | MINERVA IMAGING APS (DK) | 2019-01-17 | — | — | US | disclosed |
| EP-3402537-A1 | QUANTITATIVE PET IMAGING OF TISSUE FACTOR EXPRESSION USING 18F-LABLED ACTIVE SITE INHIBITED FACTOR VII | Rigshospitalet (DK) | 2018-11-21 | — | — | EP | disclosed |
| WO-2018091058-A1 | 177-LU LABELED ACTIVE SITE INHIBITED FACTOR VII | RIGSHOSPITALET (DK) | 2018-05-24 | — | — | WO | disclosed |
| US-20180000899-A1 | MODIFYING MACROPHAGE PHENOTYPE FOR TREATMENT OF DISEASE | APELLIS PHARMACEUTICALS, INC. | 2018-01-04 | — | — | US | disclosed |
| US-9795655-B2 | Modified MT-SP1 proteases that inhibit complement activation | CATALYST BIOSCIENCES, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| WO-2017121436-A1 | QUANTITATIVE PET IMAGING OF TISSUE FACTOR EXPRESSION USING 18F-LABLED ACTIVE SITE INHIBITED FACTOR VII | RIGSHOSPITALET (DK) | 2017-07-20 | — | — | WO | disclosed |
| EP-2433642-B1 | Modified proteases that inhibit complement activation | CATALYST BIOSCIENCES INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-5242810-A | BIFUNCTIONAL INHIBITORS OF THROMBIN AND PLATELET ACTIVATION | BIOGEN, INC. (US) | 1993-09-07 | — | — | US | disclosed |
| EP-0541058-A1 | Expression of a mature proteinase 2a, its partial purification and preparation of inhibitory active substrates | BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) | 1993-05-12 | — | — | EP | disclosed |
| US-5196404-A | Hirudin mimic, polypeptide, hirulog; bivalirudin FDA Orange book listed patent | BIOGEN, INC. (US) | 1993-03-23 | — | — | US | disclosed |
| WO-1993000926-A1 | TREATMENT OF PERIODONTAL DISEASE WITH PROTEASE INHIBITORS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1993-01-21 | — | — | WO | disclosed |
| WO-1992010575-A1 | BIFUNCTIONAL INHIBITORS OF THROMBIN AND PLATELET ACTIVATION | BIOGEN, INC. (US) | 1992-06-25 | — | — | WO | disclosed |
| EP-0489070-A1 | NOVEL INHIBITORS OF THROMBIN. | BIOGEN INC (US) | 1992-06-10 | — | — | EP | disclosed |
| WO-1991002750-A1 | NOVEL INHIBITORS OF THROMBIN | BIOGEN, INC. (US) | 1991-03-07 | — | — | WO | disclosed |
| US-4906571-A | Cell surface modification using a novel glycoproteinase of pasteurella haemolytica | UNIVERSITY OF GUELPH (CA) | 1990-03-06 | — | — | US | disclosed |
| EP-0182906-A1 | HUMAN LEUKOCYTE ELASTASE INHIBITORS PREPARED FROM PYOGENIC BACTERIA AND METHODS FOR THEIR PURIFICATION | CORTECH, INC. (US) | 1986-06-04 | — | — | EP | disclosed |
| WO-1986000077-A1 | HUMAN LEUKOCYTE ELASTASE INHIBITORS PREPARED FROM PYOGENIC BACTERIA AND METHODS FOR THEIR PURIFICATION | CORTECH, INC. (US) | 1986-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190015532-A1 | QUANTITATIVE PET IMAGING OF TISSUE FACTOR EXPRESSION USING 18F-LABLED ACTIVE SITE INHIBITED FACTOR VII | F13B, F7, F13A1 | MMP2 113/4885MMP9 123/4885PLAU 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.